May 20, 2020 / 11:13 AM / 17 days ago

BRIEF-Aldeyra Therapeutics To Test ADX-1612 Against COVID-19

May 20 (Reuters) - Aldeyra Therapeutics Inc:

* ALDEYRA THERAPEUTICS TO ADVANCE ADX-1612, AN INVESTIGATIONAL NEW HSP90 INHIBITOR WITH POTENTIAL NANOMOLAR POTENCY AGAINST SARS-COV-2, TO CLINICAL TESTING FOR COVID-19; ADX-629 ACCEPTED FOR BARDA CORONAWATCH MEETING

* ALDEYRA THERAPEUTICS INC - IND SUBMISSION FOR ADX-629 EXPECTED IN JUNE 2020

* ALDEYRA THERAPEUTICS INC - PENDING FDA FEEDBACK, IND SUBMISSION FOR ADX-1612 EXPECTED IN Q3 2020

* ALDEYRA THERAPEUTICS INC - ADX-1612 DEMONSTRATES NANOMOLAR SARS-COV-2 ANTIVIRAL POTENCY IN VITRO

* ALDEYRA THERAPEUTICS INC - ANNOUNCED PLANNED ADVANCEMENT OF INVESTIGATIONAL NEW HSP90 INHIBITOR ADX-1612 TO CLINICAL TESTING FOR COVID-19 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below